



## Oxazolone (OXA) is a respiratory allergen in Brown Norway rats

C. Frieke Kuper<sup>a,\*</sup>, Marijana Radonjic<sup>a</sup>, Jos van Triel<sup>b</sup>, Rob Stierum<sup>a</sup>, Rianne J. de Groot<sup>a,1</sup>, Josje H.E. Arts<sup>c</sup>

<sup>a</sup> TNO, Quality and Safety, Zeist, The Netherlands

<sup>b</sup> TNO Triskelion, BV, Zeist, The Netherlands

<sup>c</sup> Akzo Nobel NV, Arnhem, The Netherlands

### ARTICLE INFO

#### Article history:

Received 17 June 2011

Received in revised form 16 August 2011

Accepted 22 August 2011

Available online 26 August 2011

#### Keywords:

4-Ethoxymethylene-2-phenyl-2-oxazoline-5-one

Allergic laryngitis

Neutrophils

Gene expression

SELP

GZMB

### ABSTRACT

Oxazolone (OXA) is a potent contact allergen in man, and it is used as a model Th1-allergen to test (Q)SAR's and screening assays for allergenic potential of chemicals. However, it elevates serum IgE levels and Thelper2 cytokines at relatively low doses in test animals, suggesting that it has also respiratory allergenic potential. The lack of human data on respiratory allergenic potential of OXA may be due to lack of significant inhalation exposure. Here, female Brown Norway rats (BN) were sensitized by two or five dermal applications of OXA at the same total dose of 3.75 mg. Controls received vehicle. All animals were challenged by inhalation to 45 mg/m<sup>3</sup> OXA on day 21 and necropsy was performed on day 22. All sensitized animals had increased serum IgE. OXA challenge decreased breathing frequency, and induced apnoeic breathing in the sensitized animals – a hallmark of respiratory allergy in our model. An exudative, granulocytic inflammation was observed primarily in the larynx of the sensitized and challenged rats. Microarray analysis of lung tissue, sampled 24 h after challenge, revealed upregulation of several genes and activation of Gene Ontology (GO) pathways, which resembled more closely those found previously in lung tissue of rats sensitized and challenged by the respiratory allergen trimellitic anhydride than by the contact allergen dinitrochlorobenzene. The results indicate that the contact allergen OXA can also be a respiratory allergen, provided that it is inhaled. Its use as a model contact sensitizer must be reconsidered.

© 2011 Elsevier Ireland Ltd. All rights reserved.

### 1. Introduction

Oxazolone (OXA), 4-ethoxymethylene-2-phenyl-2-oxazoline-5-one (CAS reg. no. 15646-46-5) is a heterocyclic compound and is a chemical intermediate in the production of drugs. It is a well-known, strong contact sensitizer in man, and is frequently used as a model contact allergen in *in vivo* and *in vitro* screening assays to examine the sensitizing potential of chemicals (Roggen *et al.*, 2008). OXA has an EC3 of 0.01% in the mouse dermal LLNA (ECETOC, 2003; Van Och *et al.*, 2002). Reports on respiratory allergenic properties of OXA in humans are absent, which may indicate that OXA is indeed no respiratory allergen or that significant exposures by inhalation do not take place. In contrast to acid anhydrides and diisocyanates, OXA is not a bulk chemical and it is mostly presented as relatively large flakes.

There are no validated tests to identify the respiratory allergenic potential of chemicals, but the IgE test and cytokine fingerprinting test have been used regularly (rat: Arts and Kuper, 2007; mouse: Dearman *et al.*, 1992; Kimber *et al.*, 1996). OXA was negative in a standard IgE test in mice with two topical applications (Dearman and Kimber, 1992), but induced pronounced increases in serum IgE, especially but not exclusively after 5 and 15 times application (mouse: Webb *et al.*, 1998; rat: Mommers *et al.*, 2006). Two skin applications followed by a single intranasal challenge increased also serum IgE levels (Vanoirbeek *et al.*, 2003a,b). OXA induced the synthesis of both IFN-gamma (Th1-related) and IL-4 (Th2-related) cytokines in the lymph nodes draining the skin site of application (Thomson *et al.*, 1993). Interestingly, the OXA-induced ulcerative colitis mouse model is considered to be a Th2-mediated process (Waldner and Neurath, 2009; Heller *et al.*, 2002).

Although an increased total serum IgE level upon skin application (IgE test) has been proposed as being a predictive parameter of airway hypersensitivity caused by low molecular weight chemicals, it is unknown if total serum IgE translates directly to potential risk of inducing respiratory allergy (Farraj *et al.*, 2007, 2004; Selgrade *et al.*, 2006). Therefore, it is questionable if OXA is a respiratory

\* Corresponding author at: TNO, Quality and Safety, Research Group Quality and Safety, PO Box 360, 3700 AJ, The Netherlands. Tel.: +31 0888661736; fax: +31 0888644986.

E-mail address: [frieke.kuper@tno.nl](mailto:frieke.kuper@tno.nl) (C.F. Kuper).

<sup>1</sup> Presently: Radboud Medical University, Nijmegen, The Netherlands.

**Table 1**  
Experimental scheme.

Group designation <sup>a</sup>	Sensitization <sup>b</sup>	Day 21: challenge <sup>c</sup>	Day 22: necropsy
Veh2/OXA Unsensitized 2x/challenged	Vehicle 2x	45 mg/m <sup>3</sup> OXA	- Lung function <sup>d</sup> - Total IgE in serum
Veh5/OXA Unsensitized 5x/challenged	Vehicle 5x	45 mg/m <sup>3</sup> OXA	- Liver, kidneys, left lung weights - BAL of right lung lobes
OXA2/OXA Sensitized 2x/challenged (allergic group)	Day 0: 300 µl on flanks 1% (w/v) OXA Day 7: 150 µl on ears 0.5% (w/v) OXA (total dose 3.75 mg)	45 mg/m <sup>3</sup> OXA	- Formalin-fixation, paraffin-embedding of nasal passages, larynx, trachea (all animals) - Left lungs: 1. Formalin-fixation, paraffin-embedding (all groups; n = 3/group)
OXA5/OXA Sensitized 5x/challenged (allergic group)	Days 0, 4, 11, 14 5 × 150 µl 0.5% (w/v) OXA, alternating on flanks and ear (total dose 3.75 mg)	45 mg/m <sup>3</sup> OXA	2. Immunohisto-chemistry on snap-frozen tissue (veh5/OXA and OXA5/OXA5; n = 3/group) 3. Transcriptomics on snap-frozen tissue (veh2/OXA, OXA2/OXA, OXA2/- and OXA5/-; n = 3/group)
OXA2/- Sensitized 2x/unchallenged	Day 0: 300 µl on flanks (1%, w/v, OXA) Day 7: 150 µl on ears (0.5% (w/v) OXA (total dose 3.75 mg)	-	
OXA5/- Sensitized 5x/unchallenged	Days 0, 4, 7, 11, 14 5 × 150 µl 0.5% (w/v) OXA, alternating on flanks and ear (total dose 3.75 mg)	-	

<sup>a</sup> Six female BN rats per group.

<sup>b</sup> Vehicle acetone–olive oil (AOO) 4:1 (v/v).

<sup>c</sup> OXA dissolved in acetone, concentration based on RF test (1–50 mg/m<sup>3</sup>).

<sup>d</sup> Lung function parameters were determined before, during and after challenge.

allergen, based on increases in total serum IgE (and Th2 cytokine fingerprinting) alone.

Challenge tests in the skin and the respiratory tract are used to examine if an allergic response is really provoked in sensitized animals and if so, of what type and severity it is. Using a protocol that successfully identified respiratory allergens (rat: Arts and Kuper, 2007; Pauluhn et al., 2002; Zhang et al., 2004; mouse: Vanoirbeek et al., 2003a,b; Satoh et al., 1995) the respiratory allergen trimellitic anhydride (TMA) and the contact allergen/skin allergen dinitrochlorobenzene (DNCB) resulted in distinctly divergent responses (Arts et al., 1998; Kuper et al., 2008a,b). The divergence was also present in gene expression patterns in the lungs.

OXA was expected to behave like the respiratory allergen TMA in an inhalation challenge test as mentioned above, because of its potential to elevate IgE levels in serum. Breathing parameters, gene expression in the lungs and histopathology of the respiratory tract were examined and compared with the results found previously with the respiratory allergen TMA and the contact (skin) allergen DNCB.

## 2. Materials and methods

### 2.1. Animals and maintenance

Female, 7–8-week-old, inbred Brown Norway (BN) rats were purchased from Charles River Deutschland GmbH (Sulzfeld, Germany). The animals were acclimatized for 7 days before the start of the study. They were kept under conventional laboratory conditions and received the Institute's grain-based open-formula diet and unfluoridated tap water *ad libitum*. All animal procedures were approved by the TNO Committee of Animal Welfare.

### 2.2. Treatment schedules and groups

The study was conducted with 6 groups of rats (Table 1). Blood was collected one day before the start of the study. Female BN rats received 150 µl of oxazolone (OXA; purity 90%; Sigma–Aldrich Chemie GmbH Steinheim, Germany) in a 4:1 (v/v) mixture of acetone (Merck; Darmstadt, Germany) and refined olive oil (AOO) (Sigma Diagnostics, Inc. St. Louis, USA) as the vehicle on each flank (approximately 12 cm<sup>2</sup> each). Flanks had been shaved with an electrical razor at least 2–3 days earlier. The groups, that were sensitized twice, received 75 µl of OXA on the dorsum of both ears, seven days after the first sensitization. Groups that were sensitized five times received OXA alternating on the dorsum and the flanks (see Table 1). The sensitization concentrations were based on a preliminary study with OXA in which increased

IgE levels were observed especially after 5 and 15 times application, but two times was effective also in most of the animals, all at the same total dose of 3.75 mg (Mommers et al., 2006). On day 20 or 21, basal breathing parameters (frequency, tidal volume and pattern) were assessed, followed by OXA inhalation challenge and assessment of the same breathing parameters during and immediately post challenge. Animals were challenged by inhalation of target concentration of 50 mg/m<sup>3</sup> of OXA for 15 min. Twenty-four hours later, breathing parameters were assessed again, whereafter necropsy was performed. The challenge concentration of OXA was based on a range-finding study with four reserve rats that were exposed to 1 mg/m<sup>3</sup> on the first day, 5 mg/m<sup>3</sup> on the second day, 15 mg/m<sup>3</sup> on the third day and 50 mg/m<sup>3</sup> on the fourth day. Only the concentration of 50 mg/m<sup>3</sup> turned out to be slightly irritating (slight decreased breathing frequency) and was therefore chosen as the target concentration.

### 2.3. Atmosphere generation and analysis

During inhalation challenge, an all glass nebulizer, Institute's design, was used to generate the test atmospheres from freshly prepared solutions of OXA in acetone. The acetone concentration was kept between 3000 and 5000 ppm (~7–12 g/m<sup>3</sup>), which levels are far below the level inducing sensory irritation (Alarie, 1973). Atmospheric concentrations of OXA were determined gravimetrically by filter sampling and those of acetone by calculations based on the nominal concentration, assuming the usual 100% generation efficiency for this vapour. The particle size distribution of OXA in the test atmosphere was determined using a 10-stage cascade impactor (Andersen, Atlanta, GA). Due to the small sampling air flow rate and the large total volume required for analytical and particle size determinations, samples were not collected during the challenge itself but immediately prior to or after challenge. The mean concentration of OXA turned out to be 45 mg/m<sup>3</sup>; the mass median aerodynamic diameter (MMAD) of the aerosolized OXA particles was 0.8 µm with a geometric standard deviation (gsd) of 2.7 and 3.7.

### 2.4. Inhalation challenge and measurements of breathing parameters

Rats were individually restrained in Battelle tubes and each tube was placed into one of four whole body plethysmographs connected to the central exposure unit. Using this experimental set up, two OXA-sensitized (OXA2/OXA or OXA5/OXA) and two vehicle-treated (veh2/OXA or veh5/OXA) rats at a time were first exposed to fresh air for at least 25 min (pre-challenge period) and then to the OXA atmosphere for exactly 15 min (challenge period), followed by a recovery (post challenge) period of 30 min as described previously (Arts et al., 1998; Kuper et al., 2008a,b).

As a surrogate for changes in lung function, breathing pattern (Arts and Kuper, 2007) was monitored by means of recording the pressure signal in the plethysmographs. Frequency and tidal volume were measured and respiratory flow (minute ventilation) was calculated from the breathing pattern. Before challenge, the respiration was monitored approximately 20 s each min starting 6 min prior to the actual challenge. During challenge respiration was monitored approximately 20 s during

each min; and after challenge approximately 20 s each for the first 10 min followed by 20 s each 4 min for the remaining period of 20 min. The day after challenge, the respiration was monitored again, approximately 20 s each min for about 6 min. This resulted for each rat in 6 values prior to challenge, 15 values during and immediately after challenge, and 6 values the day after challenge, for frequency, tidal volume and respiratory flow.

### 2.5. Clinical signs, serum collection, body and organ weights, necropsy

The animals were observed daily and weighed shortly before the OXA dermal applications, at weekly intervals thereafter, and just prior to necropsy. Individual serum samples were prepared from blood withdrawn via the orbital plexus prior to sensitization, and via the abdominal aorta at necropsy. For IgE analysis, the serum samples were stored at  $-20^{\circ}\text{C}$  until analysis by Enzyme-Linked-Immuno-Sorbent Assay (ELISA). At necropsy, animals were anaesthetised with pentobarbital and killed by exsanguination from the abdominal aorta. The liver, kidneys and the unlavaged left lungs were weighed. The left lung of half of the animals (see Table 1) was inflated with 50% Tissue Tek in saline, quick-frozen on dry ice and kept at  $-70^{\circ}\text{C}$  for microarray analysis or immunohistochemistry. The nasal tissues, trachea, larynx and left lung of the other half of the animals were collected and fixated in neutral, phosphate-buffered 4% (v/v) formaldehyde for histopathological evaluation.

### 2.6. Bronchoalveolar lavage

At necropsy, the right lung lobes were lavaged two times with a volume of 23 ml saline per kg bw, after binding of the left (main) lung. The procedure was as described previously (Arts et al., 1998). Total cell numbers were counted using an automated haematology analyser (K-800, Sysmex, Toa, Kobe, Japan). For differential cell counts, cytospins were prepared and stained with May-Grünwald Giemsa. At least 200 cells were counted per animal to determine absolute numbers and percentages of macrophages/monocytes, lymphocytes, neutrophils and eosinophils.

### 2.7. Serum IgE levels

Total IgE levels in serum were analyzed by means of an ELISA as described earlier (Arts et al., 1998). The concentration of IgE in the samples was calculated using a standard curve obtained with known quantities of monoclonal rat IgE and expressed as  $\mu\text{g/ml}$  serum.

### 2.8. Histopathology and immunohistochemistry

The formalin-fixed nasal tissues, larynx, trachea and left lung were embedded in paraffin wax and sectioned at  $5\ \mu\text{m}$ . Nasal tissues were cut at 6 levels according to Woutersen et al. (1994). The larynx was cut longitudinally through the epiglottis. The cranial part of the trachea was cut transversally, the caudal part longitudinally, together with the bifurcation and the two extrapulmonary bronchi. The formalin-fixed left lung was cut longitudinally through the main bronchus/bronchiolus. The sections were stained with haematoxylin and eosin.

Cryostat sections were made from the deep-frozen left lung of three animals of the veh5/OXA and the OXA5/OXA groups (the left lungs of the other four groups were used for microarray analysis). The lung sections were stained for CD4 (W3/25), CD8 (OX8), CD161 (10/78; marker for NK cells), CD68 (marker for macrophages), or CD11b (marker for conventional dendritic cells in the lung), all from Serotec Ltd., Oxford, UK, using a 2-step indirect immunolabeling, as described previously (Kuper et al., 2008a). Positive cells were counted in the lung parenchyma at 16 square fields (square grid of  $0.3\ \text{mm}^2$ ) per left lung at  $400\times$  magnification.

### 2.9. Microarray analysis of OXA effects ('intraday comparison')

Total RNA was isolated from deep-frozen left lung tissue of three rats per group (in total 12 oxazolone treated samples; see Table 1), the samples were sent to ServiceXS BV (Leiden, The Netherlands) for cRNA synthesis and hybridization to Affymetrix Rat230.2 Chips, all as described previously (Kuper et al., 2008a,b). To pass filtering criteria, transcript was required to be detected as "present" based on MAS5 present calls in at least 1 of 12 experiments, resulting in 23283 probe sets that were considered expressed. Statistical analyses of differentially expressed genes were identified using the limma package (The Remote Analysis Computation for gene Expression data (RACE) suite at <http://race.unil.ch>). Threshold for statistical significance was set on  $p$ -value  $< 0.01$  combined with absolute fold change  $> 1.5$ . Gene expression under veh2/OXA, OXA2/- and OXA5/- treatments were compared to the OXA2/OXA treatment. To explore the variability in gene expression between the samples, principal component analysis (PCA) and hierarchical clustering were performed (GeneSpring GX 7.3.1 software; Agilent). The analysis of significantly up- or down-regulated pathways was performed using T-profiler as previously described (Kuper et al., 2008a,b). As input values, average  $\log_2$  expression ratios (2OXA/OXA versus 2OXA/-, 2OXA/OXA versus 2veh/OXA and 2OXA/OXA versus 5OXA/-) of all 23283 probe sets were used. Gene Ontology (GO) ([www.geneontology.org](http://www.geneontology.org)) pathway collection was used as source of queried gene sets. Pathways were considered significant if E-value (Bonferroni corrected) was smaller than 0.05.

### 2.10. Microarray analysis of OXA, TMA and DNCB effects ('interstudy' comparison)

The microarray data from the three OXA2/OXA BN rats were compared with those of rats treated similarly with TMA or DNCB (three TMA2/TMA and three DNCB2/DNCB rats, respectively), from two previously conducted studies (Kuper et al., 2008a,b).

To enable comparison between the effects on gene expression caused by the OXA treatments with the previously described effects observed upon TMA and DNCB treatments, data from all 36 experiments (the so-called allergic rats with their control groups, leading to 12 OXA, 12 TMA and 12 DNCB samples) were normalized together, according to the protocol for the intra-study. Accordingly, data was filtered based on MAS5 present calls to include only transcripts detected as "present" in at least 1 of 36 experiments. This resulted in 25267 probe sets that were considered expressed across oxazolone, TMA and DNCB conditions and were therefore taken into further analysis. Inter-study statistical and pathway analysis of microarray data were also performed according to the protocols for the intra-study.

### 2.11. Statistics and data analysis

Body weights were analyzed by one-way analysis of co-variance, followed by the two-sided Dunnett's multiple comparison test. Organ weights, IgE levels, BAL biochemical parameters and absolute cell numbers were determined by Anova-Dunnett's test. IgE levels were also analyzed with a 3-way ANOVA. Relative cell numbers in BAL were analyzed by Kruskal-Wallis non-parametric analysis of variance followed by a Mann/Whitney  $U$ -test. Breathing frequencies, tidal volume and respiratory flow were analyzed by a 3-way ANOVA. Time was the repeated factor and sensitization (versus non-sensitization) and numbers of sensitization (two or five times) were the between factors. Differences were considered statistically significant if  $p < 0.05$ . Analyses were performed by the usage of Graphpad Prism (Version 3.0, San Diego, CA, USA). Statistical analysis of the microarray data is described under Sections 2.9 and 2.10.

## 3. Results


### 3.1. Clinical signs, body and organ weights, and bronchoalveolar lavage

In all animals sensitized twice, dermal scaliness on the flanks was generally observed from day 4 onwards, later on (days 9–13) followed by dermal encrustations which remained till the end of the study. Dermal changes on the flanks of animals sensitized 5 time (receiving a lower dermal dose each time, see Table 1) were less in incidence and duration, as only 4 out of 12 animals showed dermal encrustations during a few days only. Gross changes were not observed after application of OXA to the ears. Body weights were not affected by the exposure to OXA. Relative liver and kidneys weights were significantly increased in sensitized rats when compared to controls (data not shown). Absolute and relative lung weights were statistically significantly increased in the OXA2/OXA group, but not in the OXA5/OXA group, when compared to their respective controls (Table 2). In the OXA2/OXA group, BAL contained an increased number of total cells, which was due to an increase in alveolar macrophages (Table 2). Other cell types were not affected (data not shown). In addition, levels of total protein and lactate dehydrogenase (LDH) were increased in the lavage fluid (data not shown). An increased number of total cells and alveolar macrophages, but without changes in protein and LDH, was also observed in the veh/OXA5 group.

### 3.2. Lung function and serum IgE levels

OXA challenge in sensitized rats induced apneic periods, i.e. irregularly lengthened pauses between varying numbers of breaths. Breathing frequency decreased to 88% of the original rate in the OXA2/OXA group and to 92% in the OXA5/OXA group, starting within 1 or 2 min of the challenge and returned to normal directly after the challenge, but increased at 24 h after challenge (Fig. 1).

Serum IgE levels (Table 2) were markedly increased in the four sensitized groups (OXA2/-; OXA2/OXA; OXA5/- and OXA5/OXA) when compared to the unsensitized groups (veh2/OXA and veh5/OXA) ( $p < 0.0001$ ; 3-way ANOVA). The increase in IgE in the



**Fig. 1.** Mean breathing frequency, tidal volume and respiratory flow  $\pm$  SD of BN rats before, during challenge, and within 30 min and 24 h after the challenge. The main effect was a change in time in sensitized animals. Frequency: time  $p < 0.001$ ; time  $\times$  sensitization  $p < 0.01$ . Tidal volume: time  $p < 0.001$ ; time  $\times$  sensitization  $p < 0.001$ ; time  $\times$  sensitization  $\times$  number of sensitizations  $p < 0.001$ ; Respiratory flow: time  $p < 0.001$ ; time  $\times$  sensitization  $p < 0.001$ ; time  $\times$  sensitization  $\times$  number of sensitizations  $p < 0.01$ , 3-way ANOVA analysis.

**Table 2**

Left lung weights, bronchoalveolar lavage parameters, and serum IgE levels in BN rats exposed to OXA.

Group <sup>a</sup>	Lung weight relative to body weight	BAL total cells ( $\times 10^6$ )	BAL macrophages ( $\times 10^6$ )	BAL total protein (mg/L)	BAL LDH (U/L)	Pre treatment total serum IgE ( $\mu$ g/ml)	After treatment total serum IgE ( $\mu$ g/ml)
Veh2/OXA	2.50 $\pm$ 0.07	0.88 $\pm$ 0.09	0.82 $\pm$ 0.09	174 $\pm$ 21	68 $\pm$ 5	0.40 $\pm$ 0.14	0.72 $\pm$ 0.19
Veh5/OXA	2.76 $\pm$ 0.08	1.37 $\pm$ 0.12**	1.30 $\pm$ 0.11*	234 $\pm$ 16	114 $\pm$ 24	0.36 $\pm$ 0.12	0.79 $\pm$ 0.21
OXA2/OXA	2.98 $\pm$ 0.07**	1.40 $\pm$ 0.11**	1.32 $\pm$ 0.11**	294 $\pm$ 21**	143 $\pm$ 25*	0.45 $\pm$ 0.13	1.78 $\pm$ 0.35**
OXA5/OXA	2.78 $\pm$ 0.11	1.08 $\pm$ 0.07	0.99 $\pm$ 0.06	258 $\pm$ 44	102 $\pm$ 12	0.30 $\pm$ 0.18	2.13 $\pm$ 0.86**
OXA2/-	2.73 $\pm$ 0.04	1.02 $\pm$ 0.09	0.96 $\pm$ 0.08	167 $\pm$ 15	65 $\pm$ 15	0.55 $\pm$ 0.32	2.01 $\pm$ 0.43**
OXA5/-	2.82 $\pm$ 0.08	1.12 $\pm$ 0.14	1.02 $\pm$ 0.12	211 $\pm$ 20	92 $\pm$ 5	0.32 $\pm$ 0.05	2.60 $\pm$ 0.69**

<sup>a</sup> Six female rats per group.

\*  $p < 0.05$ ; Anova + Dunnetts test's (two-sided).

\*\*  $p < 0.01$ ; Anova + Dunnetts test's (two-sided).

**Table 3**

Histopathological changes and their incidences in BN rats treated dermally with vehicle or OXA, left unchallenged or followed by an inhalation challenge with OXA.

	Veh2/OXA	Veh5/OXA	OXA2/OXA	OXA5/OXA	OXA2/–	OXA5/–
<i>Nasal tissues, anterior levels</i>	(6) <sup>a</sup>	(6)	(6)	(6)	(6)	(6)
Inflammatory cell infiltrates						
Very slight, focal	1	–	1	3	1	–
Very slight to slight, multifocal	–	–	5	3	–	–
<i>Larynx</i>						
Ulceration						
Slight/moderate	3	6	–	–	–	–
Severe	–	–	6	6	–	–
Mucopurulent exudate						
Slight	4	5	–	–	–	–
Severe	–	–	6	6	–	–
Inflammatory cells						
Very slight	–	1	–	–	1	1
Slight	2	2	–	–	–	1
Moderate/severe	–	–	6	6	–	–


<sup>a</sup> The number of animals examined is given in brackets.

groups sensitized twice was more than twofold, and in the groups sensitized five times it was about threefold (statistically significant difference between the groups sensitized twice and the groups sensitized five times,  $p < 0.05$ ; 3-way ANOVA).

### 3.3. Histopathology and immunohistochemistry

The unchallenged (OXA2/– and OXA5/–) animals did not exhibit histopathological changes in the respiratory tract, except for a granulomatous inflammation in the lungs, which is common in naive BN rats of this age (Germann et al., 1998).

The most prominent effect of the challenge was observed in the larynx of the sensitized (OXA2/OXA and OXA5/OXA) animals: a dense, ulcerative inflammation with exudation at the ventral side of the epiglottis and the vocal cords. Numerous granulocytes, mainly neutrophils and a few eosinophils, lymphocytes, monocytes and macrophages were observed in the mucosa of almost the entire ventral side of the epiglottis (Table 3 and Fig. 2A–D). In addition, hemorrhages were present in almost all animals. Similar epithelial effects were observed in unsensitized/challenged rats (veh2/OXA), but the number of inflammatory cells was markedly less and hemorrhages were absent. In the nasal passages, the chal-



**Fig. 2.** Histopathology of the larynx of BN rats, 24 h after challenge. The larynx is sectioned longitudinally through the epiglottis. (A) Overview of twice-sensitized, unchallenged (OXA2/–) control animal; (B) overview of unsensitized, OXA-challenged (veh2/OXA) animal with epithelial ulceration and minimal neutrophilic cell involvement, primarily at the base of the epiglottis; (C) overview of twice-sensitized, OXA-challenged (OXA2/OXA) animal with an extensive inflammation along the entire ventral side of the epiglottis. (D) Detail of the extensive inflammation in the twice-sensitized, OXA-challenged (OXA2/OXA) animal.

**Table 4**  
Differentially expressed genes in lung tissue of allergic (twice sensitized/challenged; OXA2/OXA) BN rats, 24 h after challenge.

Description	Gene name	Accession no.	Gene group/pathway (GO, KEGG)	Mean log <sub>2</sub> ratio > 1.00 <sup>a,b</sup>
Cytokine (chemokine) 10	Cxcl10/IP-10	U22520	Positive regulation of leukocyte chemotaxis; chemotaxis; inflammatory response; immune response; signal transduction. Cytokine–cytokine receptor interaction; Chemokine signaling pathway; Toll-like receptor signaling pathway; RIG-I-like receptor signaling pathway;	5.14 <sup>***</sup>
Cytokine (chemokine) 11	Cxcl11/I-TAC	BF281987	Chemotaxis; inflammatory response; chemokine activity; immune response; signal transduction; G-protein coupled receptor protein signaling pathway. Toll-like receptor signaling; cytokine–cytokine receptor interaction; Chemokine signaling pathway	5.30 <sup>***</sup>
Cytokine (chemokine) 9	Cxcl9	AI044222	Chemotaxis; defense response; inflammatory response; immune response; cellular defense response. Cytokine–cytokine receptor interaction; chemokine signaling pathway; Toll-like receptor signaling pathway	3.96 <sup>***</sup>
Ubiquitin D	Cxcl9 Ubd	AI170387 NM.053299	Antimicrobial humoral response; protein modification process; proteolysis	3.80 <sup>***</sup> 3.78 <sup>***</sup>
Cytokine (chemokine) 7 – monocyte chemotactic protein 3	Ccl7/MCP3/SCYA7	BF419899	Cellular calcium ion homeostasis; chemotaxis; chemokine activity; immune response; inflammatory response; signal transduction. Cytokine–cytokine receptor interaction; Chemokine signaling pathway; NOD-like receptor signaling pathway	2.69 <sup>†</sup>
Agtrin	G1p2_predicted	BE096523	Plasma membrane organization; signal transduction; muscarinic acetylcholine receptor signaling; synapse assembly; neuromuscular junction development. ECM-receptor interaction	2.14 <sup>***</sup>
Similar to Ac2-233 Homologous to some human interferon-inducible proteins	Igtp_predicted MGC94037	BI300770 AW531805	–	–2.09 <sup>**</sup> 1.89 <sup>***</sup>
Similar to interferon-inducible GTPase	MGC108823 RGD1309362	AI408440 AA955213	–	1.80 <sup>***</sup> 1.71 <sup>***</sup>
Proteasome subunit, beta type 9	Psmb9	AI599350	Immune response; antigen processing and presentation; anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; interspecies interaction between organisms; negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle.	1.68 <sup>***</sup>
Granzyme B	Gzmb	M34097	Apoptosis; extracellular space; proteolysis; cleavage of lamin; serine-type (endo)peptidase activity; natural killer cell mediated cytotoxicity; type I diabetes mellitus; autoimmune thyroid disease; allograft rejection	1.60 <sup>***</sup>
Interferon regulatory factor 7 (predicted)	Irf7_predicted	BF411036	Negative regulation of transcription from RNA polymerase II promoter; regulation of transcription, DNA-dependent; response to virus; immunoglobulin mediated immune response; interspecies interaction between organisms. Toll-like receptor signaling pathway; RIG-I-like receptor signaling pathway; Cytosolic DNA-sensing pathway	1.44 <sup>***</sup>
Granzyme B Signal transducer and activator of transcription 1	Gzmb Stat1	AI029386 AW434718	See above under 'Granzyme B M34097' Regulation of transcription, DNA-dependent; transcription from RNA polymerase II promoter; induction of apoptosis; activation of caspase activity; signal transduction. Chemokine signaling pathway; Toll-like receptor signaling pathway; Jak-STAT signaling pathway; pathways in cancer	1.36 <sup>***</sup> 1.27 <sup>***</sup>
Ubiquitin-activating enzyme E1-like (predicted)	Ube1l_predicted	AI177396	–	1.21 <sup>***</sup>
Granzyme M Signal transducer and activator of transcription 1	Gzmm Stat1	L05175 BM386875	Cytolysis; proteolysis; extracellular space See above under 'Stat1 AW434718'	1.20 <sup>**</sup> 1.20 <sup>**</sup>
Interferon regulatory factor 1	Irf1	NM.012591	Immune response; negative regulation of progression through cell cycle; positive regulation of IL-12 biosynthesis; regulation of transcription, DNA-dependent; transcription from RNA polymerase II promoter; CD8-positive, alpha-beta T cell differentiation	1.19 <sup>***</sup>
Guanylate nucleotide binding protein 2 Similar to hypothetical protein MGC29390	Gbp2 RGD1310490	NM.133624 BF284106	Immune response	1.19 <sup>***</sup> 1.18 <sup>***</sup>
Natural killer cell group 7 sequence	Nkg7	NM.133540	Extracellular space; integral to membrane	1.17 <sup>**</sup>
Uridine phosphorylase 1 (predicted)	Upp1_predicted	BI292558	Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process; pyrimidine nucleotide metabolic process; nucleoside metabolic process; nucleotide catabolic process; uridine metabolic process. Pyrimidine metabolism; Drug metabolism - other enzymes; Metabolic pathways	1.12 <sup>**</sup>
Similar to 5830458K16Rik protein (predicted)	RGD1306974_predicted	AA819788	–	1.12 <sup>***</sup>
Putative ISG12(b) protein	Isg12(b)/Ifi2712	AA819034	Membrane; integral to membrane	1.05 <sup>***</sup>

<sup>a</sup> OXA2/OXA versus veh2/OXA.

<sup>b</sup> Significances \*\*\**p* < 0.001; \*\**p* < 0.01 or \**p* < 0.05 OXA2/OXA versus either of all intrastudy control groups (veh2/OXA, OXA2/– and OXA5/–).

**Table 5**

T-values of differentially expressed groups of genes (Gene Ontology) in left lung tissue of BN rats, sensitized twice and subsequently challenged with OXA (OXA2/OXA).

GO ontology pathway	OXA2/OXA versus OXA2/–	OXA2/OXA versus OXA5/–	OXA2/OXA versus veh2/OXA
Chemokine activity	14.41***	8.36***	14.91***
Chemokine receptor binding	14.16***	7.88***	14.59***
Immune response	10.57***	4.75*	17.00***
Cytokine activity	8.09***	5.12*	8.02***
Defense response	7.18***	0.05	10.67***
Inflammatory response	6.18***	–0.46	8.89***
Extracellular matrix	–5.28**	–8.52***	–3.80
Blood vessel development	–5.71***	–5.48***	3.44
Anatomical structure development	–6.49***	–8.42***	–1.08
Muscle contraction	–3.91	–9.63***	–6.53***

\*\* E-value &lt; 0.001.

\*\*\* E-value &lt; 0.0001.

lunge in the sensitized animals caused a very slight to slight mixed granulocytic–monocytic inflammatory cell infiltrate, whereas in the unsensitized animals (veh2/OXA and veh5/OXA) the inflammation was only very slight (Table 3). Moreover, the inflammatory cell infiltrates in the unsensitized animals were only focal, whereas the infiltrates in about half of the sensitized animals were multifocal. The infiltrates in the sensitized animals did not show a distinct predilection site, other than being located in the anterior part of the nasal passages (Levels 1–3): they were observed ventrally on the septum, the lateral wall and/or the maxilla- and nasal turbinates. Challenge-related effects were not observed in the H&E-stained sections of the trachea and lungs.

The number of immunohistochemically stained CD4<sup>+</sup>, CD8<sup>+</sup>, CD161<sup>+</sup>, and CD68<sup>+</sup> cells in the alveolar septa of the left lungs did not differ between the sensitized (OXA5/OXA) and unsensitized (veh5/OXA) animals. The number of CD11b<sup>+</sup> cells was slightly lower in the sensitized animals (OXA5/OXA: 70.7 ± 2.1 and veh5/OXA: 81.7 ± 2.9 per total surface area of 1.4 mm<sup>2</sup>).

### 3.4. Effect of OXA on lung tissue transcriptome

#### 3.4.1. Intrastudy comparison: single genes analysis


Comparison between the groups resulted in total of 1150 differentially expressed genes in at least one of the veh2/OXA, OXA2/– and OXA5/– treatments compared to the sensitized/challenged group (OXA2/OXA). The genes affected most are listed in Table 4. The mean fold changes were highest for the cytokines Cxcl9, Cxcl10 and Cxcl11 and for ubiquitin.

#### 3.4.2. Gene group analysis

The GO Ontology groups/pathways of genes ‘Chemokine activity’, ‘Chemokine receptor binding’, ‘Immune response’ and ‘Cytokine activity’ were upregulated considerably, and highly significantly in the OXA2/OXA group, compared to the other three groups (Table 5). The pathways ‘extracellular matrix’, ‘blood vessel development’, ‘anatomical structure development’ and ‘muscle contraction’ were downregulated significantly compared to two of the groups (Table 5).

#### 3.4.3. Interstudy comparison

Single gene comparison between OXA, TMA and DNCB (groups sensitized/challenged versus unsensitized/challenged rats) revealed an overlap of 112 genes between OXA and TMA, and 6 of these genes were shared by OXA, DNCB and TMA (Fig. 3 and Table 6). The overall gene expression profile of OXA resembled more that of TMA than of DNCB.



**Fig. 3.** The number of genes differentially expressed by OXA, TMA and DNCB in the twice-sensitized and challenged (compound 2x/compound) groups compared to the unsensitized, but challenged (veh2x/compound) groups, and the number of genes shared by OXA, TMA and/or DNCB.

## 4. Discussion

The breathing pattern, IgE levels and inflammation induced by OXA in this study indicated that OXA behaved comparable to the respiratory allergen TMA in previous studies, using the same protocol (Arts et al., 1998, 2003, 2004; Kuper et al., 2008a). Animals sensitized five times had higher IgE levels and tended to have a more decreased breathing frequency during challenge than animals sensitized twice, but the type and degree of inflammation was unaffected by the number of sensitizations.

The allergic inflammation induced by the inhalation challenge of OXA in the OXA-sensitized animals was localized primarily in the larynx. Allergic laryngitis was observed also in TMA-allergic Brown Norway rats and DNCB-allergic Wistar rats. Allergic laryngitis is not diagnosed often in man, perhaps because particle impaction patterns in the respiratory tract differ from those of rats. However, it is more plausible that the reported low incidence in man is due to underdiagnosis of allergic laryngitis (Hellings and Fokkens, 2006; Krouse and Altman, 2010; Leino et al., 1998; Randhawa et al., 2010).

**Table 6**  
Overlap of genes in lung tissue of allergic (twice sensitized/challenged) BN rats: comparison OXA, TMA and/or DNCB.<sup>a</sup>

Description <sup>b</sup>	Gene name	Accession no.	Description
<i>The most significant differentially expressed genes shared by OXA and TMA, but not DNCB<sup>c</sup></i>			
	Cxcl9	AI170387	
	Cxcl10	U22520	
	Cxcl11	BF281987	
Amiloride binding protein 1	Abp1	NM.022935	Amine metabolic process; oxidation reduction, arginine and proline metabolism; histidine metabolism; tryptophan metabolism
	G1p2-predicted	BE096523	
	Gbp2	NM.133624	
	Irf1	NM.012591	
	Irf7-predicted	BF411036	
	Isg12(b)/Iif2712	AA819034	
Interferon inducible protein 1 (predicted)	Ifl1-predicted	AI407339	Autophagy; inflammatory response; innate immune response
Oligoadenylate synthetase-like 1	Oasl1-predicted	BF419319	
Proteasome (prosome, macropain) subunit, beta type, 8	Psmb8	NM.080767	Immune response; antigen processing and presentation, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; interspecies interaction between organisms; negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle
	Psmb9	AI599350	
–	Psmb10-predicted	BG373505	–
Member RAS oncogene family	Rab20-predicted	BI293985	Intracellular protein transport; nucleocytoplasmic transport; signal transduction; small GTPase mediated signal transduction; protein transport
Signal transducer and activator of transcription 2	Stat2-predicted	BG666368	Regulation of transcription, DNA-dependent; regulation of transcription from RNA polymerase II promoter; signal transduction; JAK-STAT cascade; chemokine signaling pathway; Jak-STAT signaling pathway
Selectin P	Selp	BI296054	Positive regulation of leukocyte migration; regulation of cellular extravasation; inflammatory response; cell adhesion; heterophilic cell–cell adhesion.
Transporter 1	Tap1	X57523	Protein complex assembly; transport; intracellular protein transport; defense response; immune response. ABC transporters; antigen processing and presentation; primary immunodeficiency
Transporter 2	Tap2	NM.032056	positive regulation of T cell mediated cytotoxicity; response to molecule of bacterial origin; antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent; protein complex assembly; positive regulation of antigen processing and presentation of peptide antigen via MHC class I. ABC transporters; Antigen processing and presentation; Primary immunodeficiency
TNF receptor superfamily member; B-cell surface antigen CD40	Tnfrsf5-predicted/CD40	AW433947	Immune response-regulating cell surface receptor signaling pathway; protein complex assembly; inflammatory response; platelet activation; positive regulation of B cell proliferation. Cytokine–cytokine receptor interaction; Cell adhesion molecules; Toll-like receptor signaling pathway; Intestinal immune network for IgA production; asthma
	Upp1-predicted	BI292558	
Superoxide dismutase 3, extracellular	Sod3 (down-regulated)	NM.012880	Response to hypoxia; superoxide metabolic process; response to copper ion; oxidation reduction
Engulfment adaptor PTB	Gulp1-predicted (down-regulated)	BM390519	Lipid transport; phagocytosis, engulfment; apoptosis; metabolic process; oxidation reduction
Flavin containing monooxygenase 2 (non-functional); pulmonary flavin-containing monooxygenase	Fmo2 (down-regulated)	BM389350	Organic acid metabolic process; NADP metabolic process; oxygen and reactive oxygen species metabolic process; xenobiotic metabolic process; toxin metabolic process; Drug metabolism – cytochrome P450
<i>The six differentially expressed genes shared by OXA, TMA and DNCB</i>			
	Ubd	NM.053299	
	Gzmb	AI029386	
	Ccl7/MCP3	BF419899	
Runt-related transcription factor	Runx3	AI709792	Regulation of transcription, DNA-dependent; transcription from RNA polymerase II promoter; induction of apoptosis; axon guidance; cell proliferation
–	RGD1309596-predicted	BG377140	–
–	NA	AW525366	–

<sup>a</sup> For all three allergens, the same protocol was used. The genes were measured in lung tissue, 24 h after challenge with the allergen.

<sup>b</sup> Only for the genes not included in Table 4.

<sup>c</sup> Of the 106 genes expressed by both OXA and TMA, 24 genes were selected on the basis of (i) being significantly expressed in the twice sensitized/challenged groups (OXA- and TMA-allergic rats) compared to all other groups, (ii) expressed in the same direction (up- or down-regulated for both OXA and TMA), and (iii) at  $p < 0.01$ .

The histopathology of the laryngitis pointed to an intriguing aspect of respiratory allergy. The challenge with OXA induced large numbers of neutrophils in the larynx of the sensitized animals, but some neutrophils were observed in the unsensitized animals as well (Fig. 2), suggesting that the sensitization made the animals exceptionally sensitive for the irritating properties of OXA. This sensitization-aggravated irritation is in line with the concept proposed by Noble (2009) that there may be memory for danger signals

as well as for specific antigens. The concept of Noble (2009) could explain the presence of the large numbers of neutrophils in the OXA-induced allergic laryngitis as well as the neutrophils in moderate to severe asthma and the aspecific hyperreactivity (AHR) in asthmatic individuals.

The development of respiratory allergy is considered to be regulated predominantly by Th2-polarized immune reactions in which IgE plays a dominant role. The OXA-induced increased total IgE

levels in serum and the breathing pattern were in line with a Th2-polarized mechanism. Neutrophils in the lungs are associated with certain types of Th2-mediated asthma, but also with Th1-mediated hypersensitivity pneumonitis/allergic alveolitis (HP/AA; De Vooght et al., 2011; Fireman, 2006; Matsuoka et al., 2010). The observed hemorrhages in the OXA-induced laryngitis are more in line with the hemorrhages found in the lungs of acute and subchronic HP/AA patients (Bogaert et al., 2009; Jancar and Crespo, 2005). This complex picture is in accordance with the increasing awareness that lung allergies like asthma and HP/AA have considerable overlap in pathogenesis and histopathology, depending on the severity and chronicity of the diseases and this may be the case with laryngeal allergies as well.

In the present study, allergic inflammation was not observed in the lungs of the OXA-sensitized and -challenged rats, but microarray analysis of lung tissue revealed strong upregulation of several genes (Table 4). There was considerable overlap between OXA- and TMA-induced differentially expression of genes (Table 6), although TMA induced more strongly Th2-associated genes and OXA Th1-associated genes, namely Cxcl9, Cxcl10 and Cxcl11 (Table 4). These genes are regulated by STAT1 (Chen and Hershey, 2007; Fulkerson et al., 2004; Mikhak et al., 2006). Interestingly, these genes were not upregulated by the contact allergen DNCB (Table 6). This in accordance to the findings of Ku et al. (2009), who found Cxcl9 and Cxcl10 upregulation in the skin by OXA and TDI but not by DNCB. Cxcl10 has been found in a murine asthma model (Fulkerson et al., 2004) and in the late-phase reaction in human asthmatic lung (Lai et al., 2008). The Th1-related chemokines may reflect a negative feedback mechanism by which Th1 counterbalances Th2 to self-limit the allergic inflammation (Dharajiva et al., 2009; Wells et al., 2007). OXA and TMA induced upregulation of Ccl7 (Table 6), which is consistently associated with respiratory allergy (Bloemen et al., 2007; Fulkerson et al., 2004; Johnson et al., 2004), but so did DNCB. In contrast to TMA, OXA did not activate the known pathways for remodeling, which is considered a significant health aspect of asthma (Davies et al., 2003). However, shared genes like SELP and GZMB suggest that OXA, like TMA, interfered with vascular permeability and leukocyte extravasation and maybe even lung remodeling via platelet activation (Pitchford et al., 2008).

Although the GO Ontology pathways related to chemokines were strongly upregulated in the OXA-sensitized and -challenged rats, no genes were identified for those chemokines that are being used in current cytokine profiling tests for distinguishing typical respiratory from typical contact allergens. In addition, the genes and pathways were dissimilar to those found by Verstraelen et al. (2009a,b,c) in *in vitro* studies, exposing macrophages and epithelial cells to chemical respiratory allergens. Microarray analyses have not provided us yet with markers to be applied in a robust test to identify respiratory allergens, but they clearly add in our understanding of the complex issue of respiratory allergy.

In summary, the sensitizer OXA behaved like the respiratory allergen TMA in our inhalation challenge model in rats, with respect to the induction of elevated serum IgE levels and apneas, and the type of allergic laryngeal inflammation. However, microarray analysis of the lung suggested that OXA acts through different mechanisms than TMA, although the overlap in genes and pathways between OXA and TMA was larger than with the contact allergen DNCB. It is possible that the variability in balance between Th1- and Th2-associated genes reflects different subtypes of respiratory allergies (Bogaert et al., 2009; Truyen et al., 2006). It is concluded that, although the mechanisms may differ from those induced by the recognized respiratory allergen TMA, OXA has respiratory allergenic potential and should therefore not be used as a model contact allergen to develop and validate (Q)SAR models and *in vivo* and *in vitro* screening tests to identify sensitization potential of chemicals.

## Conflict of interest

All authors declare that there is no conflict of interest.

## Acknowledgements

The authors gratefully acknowledge the CEFIC-LRI Brussels, Belgium, and the Dutch Ministry of Social Affairs and Employment for financial support. The authors thank E. Duistermaat, L. van Oostrum, G. Roverts and M. Schijf for expert technical assistance.

## References

- Alarie, Y., 1973. Sensory irritation by airborne chemicals. *CRC Crit. Rev. Toxicol.* 2, 299–363.
- Arts, J.H.E., Kuper, C.F., Spoor, S., Bloksma, N., 1998. Airway morphology and function of rats following dermal sensitization and respiratory challenge with low molecular weight chemicals. *Toxicology* 152, 66–76.
- Arts, J.H.E., Bloksma, N., Leusink-Muis, T., Kuper, C.F., 2003. Respiratory allergy and pulmonary irritation to trimellitic anhydride in brown Norway rats. *Toxicol. Appl. Pharmacol.* 187, 38–49.
- Arts, J.H.E., Koning de, M.W., Bloksma, N., Kuper, C.F., 2004. Respiratory allergy to trimellitic anhydride in rats: concentration–response relationships during elicitation. *Inhal. Toxicol.* 16, 259–269.
- Arts, J.H.E., Kuper, C.F., 2007. Animal models to test respiratory allergy to low molecular weight chemicals: a guidance. *Methods* 41, 61–71.
- Bloemen, K., Verstraelen, S., Van den Heuvel, R., Witters, H., Nelissen, I., Schoeters, G., 2007. The allergic cascade: review of the most important molecules in the asthmatic lung. *Immunol. Lett.* 113, 6–18.
- Bogaert, P., Tournoy, K.G., Naessens, T., Grooten, J., 2009. Where asthma and hypersensitivity pneumonitis meet and differ. *Am. J. Pathol.* 174, 3–13.
- Chen, W., Hershey, G.K.K., 2007. Signal transducer and activator of transcription signals in allergic disease. *J. Allergy Clin. Immunol.* 119, 529–541.
- Davies, D.E., Wicks, J., Powell, R.M., Puddicombe, S.M., Holgate, S.T., 2003. Airway remodeling in asthma: new insights. *J. Allerg. Clin. Immunol.* 111, 215–226.
- Dharajiva, N., Vaidya, S., Sinha, M., Luxon, B., Boldogh, I., Sur, S., 2009. Allergen challenge induces Irfng dependent GTPases in the lungs as part of a Th1 transcriptome response in a murine model of allergic asthma. *Plos One* 4, 1–8.
- Dearman, R.J., Kimber, I., 1992. Divergent immune responses to respiratory and contact chemical allergens: antibody elicited by phthalic anhydride and oxazolone. *Clin. Exp. Allergy* 22, 241–250.
- Dearman, R.J., Basketter, D.A., Kimber, I., 1992. Variable effects of chemical allergens on serum IgE concentration in mice. Preliminary evaluation of a novel approach to the identification of respiratory sensitizers. *J. Appl. Toxicol.* 317–323.
- De Vooght, V., Haenen, S., Verbeken, E., Nemery, B., Hoet, P.H.M., Vanoirbeek, J.A.J., 2011. Successful transfer of chemical-induced asthma by adoptive transfer of low amounts of lymphocytes in a mouse model. *Toxicology* 279, 85–90.
- ECETOC, 2003. Contact sensitisation: classification according to potency. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium, Technical Report No. 87.
- Farraj, A.K., Harkema, J.R., Kaminski, N.E., 2004. Allergic rhinitis induced by intranasal sensitization and challenge with trimellitic anhydride but not with dinitrochlorobenzene or oxazolone in A/J mice. *Toxicol. Sci.* 79, 315–325.
- Farraj, A.K., Boykin, E., Haykal-Coates, N., Gavett, S.H., Doerfler, D., Selgrade, M., 2007. Th2 cytokines in skin draining lymph nodes and serum IgE do not predict airway hypersensitivity to intranasal isocyanate exposure in mice. *Toxicol. Sci.* 100, 99–108.
- Fireman, P., 2006. Atlas of Allergies and Clinical Immunology. Mosby Elsevier, Philadelphia, US.
- Fulkerson, P.C., Zimmerman, N., Hassman, L.M., Finkelman, F.D., Rothenberg, M.E., 2004. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN $\gamma$ . *J. Immunol.* 173, 7565–7574.
- Germann, P.-G., Haefner, D., Hanauer, G., Drommer, W., 1998. Incidence and severity of granulomatous pneumonia in Brown Norway (BN) rats: breeder related variations. *J. Exp. Anim. Sci.* 39, 22–33.
- Heller, F., Fuss, I.J., Nieuwenhuis, E.E., Blumberg, R.S., Strober, W., 2002. Oxazolone colitis, a Th2 model resembling ulcerative colitis, is mediated by IL-13 producing NK-T cells. *Immunity* 17, 629–638.
- Hellings, J., Fokkens, W., 2006. Allergic rhinitis and its impact on otorhinolaryngology. *Eur. J. Allergy Clin. Immunol.* 61, 6.
- Jancar, S., Sanchez Crespo, M., 2005. Immune complex-mediated tissue injury: a multistep paradigm. *Trends Immunol.* 26, 48–55.
- Johnson, V.J., Matheson, J.M., Luster, M.I., 2004. Animal models for diisocyanate asthma: answers for lingering questions. *Curr. Opin. Allergy Clin. Immunol.* 4, 105–110.
- Kimber, I., Hilton, J., Basketter, D.A., Dearman, R.J., 1996. Predictive testing for respiratory sensitization in the mouse. *Toxicol. Lett.* 86, 193–198.
- Krouse, J.H., Altman, K.W., 2010. Rhinogenic laryngitis, cough and the unified airway. *Otolaryngol. Clin. North America* 43, 111–121.
- Ku, H.-U., Jeong, S.-H., Kang, H.-G., Pyo, H.-M., Cho, J.-H., Son, S.-W., Yun, S.M., Ryu, D.-Y., 2009. Gene expression profiles and pathways in skin inflammation induced by three different sensitizers and an irritant. *Toxicol. Lett.* 190, 231–237.

- Kuper, C.F., Heijne, W.H.M., Dansen, M., Verhoeckx, K.C.M., Boorsma, A., Radonjic, M., Bruijntjes, J.P., Stierum, R., Muijser, H., Arts, J.H.E., 2008a. Molecular characterization of trimellitic anhydride-induced respiratory allergy in Brown Norway rats. *Toxicol. Pathol.* 36, 985–999.
- Kuper, C.F., Stierum, R.H., Boorsma, A., Schijf, M.A., Prinsen, M., Bruijntjes, J.P., Bloksma, N., Arts, J.H.E., 2008b. The contact allergen dinitrochlorobenzene (DNCB) and respiratory allergy in the Th2-prone Brown Norway rat. *Toxicology* 246, 213–221.
- Lai, S.-T., Hung, C.-H., Hua, Y.-M., Hsu, S.-H., Jong, Y.-J., Suen, J.-L., 2008. T-helper 1-related chemokines in the exacerbation of childhood asthma. *Pediatr. Intern.* 50, 99–102.
- Leino, T., Tammilehto, L., Hytonen, M., Sala, E., Paakulainen, H., Kanerva, L., 1998. Occupational skin and respiratory diseases among hairdressers. *Scand. J. Work. Environ. Health* 24, 398–406.
- Matsuoka, H., Niimi, A., Matsumoto, H., Takemura, M., Yamaguchi, M., Jinnai, M., Inoue, H., Ito, I., Chin, K., Mishima, M., 2010. Inflammatory subtypes in cough-variant asthma: association with maintenance doses of inhaled corticosteroids. *Chest* 138, 1418–1425.
- Mikhak, Z., Fleming, C.M., Medoff, B.D., Thomas, S.Y., Tager, A.M., Campanella, G.S., Luster, A.D., 2006. STAT1 in peripheral tissue differentially regulated homing of antigen-specific Th1 and Th2 cells. *J. Immunol.* 176, 4959–4967.
- Mommers, C., Arts, J., Schijf, M., Kuper, F., 2006. Exposure is the proof of the pudding: oxazolone is a potential respiratory allergen. *Toxicologist (Suppl. Tox. Sci.)* 90, 76.
- Noble, A., 2009. Do we have memory of danger as well as antigen? *Trends Immunol.* 30, 150–156.
- Pauluhn, J., Eidmann, P., Freyberger, G., Wasinska-Kempka, G., Vohr, H.W., 2002. Respiratory hypersensitivity to trimellitic anhydride in brown Norway rats: a comparison of endpoints. *J. Appl. Toxicol.* 22, 89–97.
- Pitchford, S.C., Momi, S., Baglioni, S., Casali, L., Giannini, S., Rossi, R., Page, C.P., Gresele, P., 2008. Allergen induces the migration of platelets to lung tissue in allergic asthma. *Am. J. Respir. Crit. Care Med.* 177, 604–612.
- Randhawa, P.S., Nouraei, S., Mansuri, S., Rubin, J.S., 2010. Allergic laryngitis as a cause of dysphonia: a preliminary report. *Logoped. Phoniatrics Vocol.* 35, 169–174.
- Roggen, E., Aufderheide, M., Cetin, Y., Dearman, R.J., Gibbs, S., Hermanns, I., Kimber, I., Regal, J.F., Rovida, C., Warheit, D.B., Uhlig, S., Casati, S., 2008. The development of novel approaches to the identification of chemical and protein respiratory allergens. *ATLA* 36, 591–598.
- Satoh, T., Kramarik, J.A., Tollerud, D.J., Karol, M.H., 1995. A murine model for assessing the respiratory hypersensitivity potential of chemical allergens. *Toxicol. Lett.* 78, 57–66.
- Selgrade, M.K., Boykin, E.H., Haykal-Coates, N., Woolhiser, M.R., Wiescinski, C., Andrews, D.L., Farraj, A.K., Doerfler, D.L., Gavett, S.H., 2006. Inconsistencies between cytokine profiles, antibody responses, and respiratory hyperresponsiveness following dermal exposure to isocyanates. *Toxicol. Sci.* 94, 108–117.
- Thomson, J.A., Trout, A.B., Kelso, A., 1993. Contact sensitization to oxazolone: involvement of both interferon- $\gamma$  and interleukin-4 in oxazolone-specific Ig and T-cell responses. *Immunology* 78, 185–192.
- Truyen, E., Coteur, L., Dilissen, E., Overbergh, L., Dupont, L.J., Ceuppens, J.L., Bul-lens, D.M.A., 2006. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. *Thorax* 61, 202–208.
- Van Och, F.M., Van Loveren, H., De Jong, W.H., Vandebriel, R.J., 2002. Cytokine production induced by low-molecular-weight chemicals as a function of the stimulation index in a modified local lymph node assay: an approach to discriminate contact sensitizers from respiratory sensitizers. *Toxicol. Appl. Pharmacol.* 184, 46–56.
- Vanoirbeek, J.A.J., Mandervelt, C., Cunningham, A.R., Hoet, P.H.M., Xu, H., Vanhooren, H.M., Nemery, B., 2003a. Validity of methods to predict the respiratory sensitizing potential of chemicals: a study with a piperidiny chlorotriazine derivative that caused an outbreak of occupational asthma. *Toxicol. Sci.* 76, 338–346.
- Vanoirbeek, J.A.J., Tarkowski, M., Ceuppens, J.L., Verbeken, E.K., Nemery, B., Hoet, P.H.M., 2003b. Respiratory response to toluene diisocyanate depends on prior frequency and concentration of dermal sensitization in mice. *Toxicol. Sci.* 80, 310–321.
- Verstraelen, S., Nelissen, I., Hooyberghs, J., Witters, H., Schoeters, G., Van Cauwenberghe, P., Van den Heuvel, R., 2009a. Gene profiles of THP-1 macrophages after in vitro exposure to respiratory (non-)sensitizing chemicals: identification of discriminating genetic markers and pathway analysis. *Toxicol. In Vitro* 23, 1151–1162.
- Verstraelen, S., Nelissen, I., Hooyberghs, J., Witters, H., Schoeters, G., Van Cauwenberghe, P., Van den Heuvel, R., 2009b. Gene profiles of a human alveolar epithelial cell line after in vitro exposure to respiratory (non-)sensitizing chemicals: identification of discriminating genetic markers and pathway analysis. *Toxicol. In Vitro* 23, 1151–1162.
- Verstraelen, S., Nelissen, I., Hooyberghs, J., Witters, H., Schoeters, G., Van Cauwenberghe, P., Van den Heuvel, R., 2009c. Gene profiles of a human bronchial epithelial cell line after in vitro exposure to respiratory (non-)sensitizing chemicals: Identification of discriminating genetic markers and pathway analysis. *Toxicol. In Vitro* 23, 1151–1162.
- Waldner, M.J., Neurath, M.F., 2009. Chemically-induced mouse models of colitis. *Curr. Protocols Pharmacol. Suppl.* 46, 1–15.
- Webb, E.F., Tzimas, M.N., Newsholme, S.J., Griswold, D.E., 1998. Intralésional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor  $\alpha$  and interleukin-4. *J. Invest. Dermatol.* 111, 86–92.
- Wells, J.W., Cowled, C.J., Giorgini, A., Kemeny, D.M., Noble, A., 2007. Regulation of allergic airway inflammation by class I-restricted allergen presentation and CD8 T-cell infiltration. *J. Allergy Clin. Immunol.* 119, 226–234.
- Woutersen, R.A., van Garderen-Hoetmer, A., Slootweg, P.J., Feron, V.J., 1994. Upper respiratory tract carcinogenesis in experimental animals and humans. In: Waalkens, M.P., Ward, J.M. (Eds.), *Carcinogenesis, Target Organ Toxicology Series*. Raven Press, New York, pp. 27–36.
- Zhang, X.D., Fedan, J.S., Lewis, D.M., Siegel, P.D., 2004. Asthmalike biphasic airway responses in Brown Norway rats sensitized by dermal exposure to dry trimellitic anhydride powder. *J. Allergy Clin. Immunol.* 113, 320–326.